MedTrace Logo

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

NCT05328726 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-03-23

No results posted yet for this study

Summary

Single ascending dose first time in human study for GZR18 in healthy subjects

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

GZR-18

As previously described in Arms

OTHER

Placebo

Placebo will be dosed in an identical manner to active study drug.

Sponsors & Collaborators

  • Gan and Lee Pharmaceuticals, USA

    lead INDUSTRY

Principal Investigators

  • Kimberly Lazaroff, MSN · Gan and Lee Pharmaceuticals, USA Corp

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-08
Primary Completion
2023-02-09
Completion
2023-03-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05328726 on ClinicalTrials.gov